| Similar Articles |
|---|
 |
The Motley Fool
August 31, 2007
Brian Lawler |
4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals.   |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
November 20, 2006
Brian Lawler |
One-and-a-Half Setbacks for Exelixis Drug development is a long process usually involving many setbacks and failures, even for the most successful drug makers. Investors in this biotech shouldn't worry too much about this one. |
The Motley Fool
June 5, 2007
Brian Lawler |
Exelixis Presents The pharmaceutical presents data from 2 of its top drug candidates at ASCO. Investors, take note. |
The Motley Fool
July 22, 2008
Brian Lawler |
Anxiously Awaiting Exelixis Pivotal clinical trial results for a top drug are finally within sight. Investors, take note. |
The Motley Fool
January 3, 2007
Brian Lawler |
Exelixis Busy Selling Its Wares Exelixis inked another development deal with biopharma powerhouse Genentech. Investors, take note. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
November 19, 2010
Brian Orelli |
Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all. |
The Motley Fool
November 7, 2007
Brian Lawler |
Following Up on Exelixis Budding development stage pharma Exelixis announces its third-quarter financial results and updates investors on what they can expect for the rest of the year. |
The Motley Fool
July 10, 2008
Brian Lawler |
Lilly Targets a Tiny Prize As drugmakers go, this acquisition's a value meal. |
The Motley Fool
October 1, 2008
Brian Orelli |
3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear. |
The Motley Fool
May 29, 2009
Brian Orelli |
This Company Is Hot and Going Places Pharma company sanofi-aventis licenses a program, including two phase 1 compounds from Exelixis. |
The Motley Fool
August 8, 2007
Brian Lawler |
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. |
The Motley Fool
December 21, 2011
Brian Orelli |
A Biotech Garage Sale Exelixis sells off a preclinical program. |
The Motley Fool
April 2, 2008
Brian Lawler |
A Slate of Data for Exelixis Exelixis will present analyses of study data at the American Society of Clinical Oncology in May for all of its lead cancer-fighting compounds. Investors, take note. |
The Motley Fool
November 26, 2010
Brian Orelli |
Black Friday Biotech Bargains Drugmakers on sale. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
The Motley Fool
December 17, 2007
Brian Lawler |
Glaxo, Exelixis Trade Gifts Glaxo announces that it will take over development of a lead Exelixis drug. |
The Motley Fool
December 12, 2008
Brian Orelli |
An EXELent Drug Deal Exelixis picks up $195 million in cash in a licensing deal with Bristol-Myers Squibb. |
The Motley Fool
June 6, 2006
Brian Lawler |
Exelixis' Continued Excellence The company reported preliminary phase 1 results for three of its lead compounds. Until investors see the results from phase 2 trials, they should chalk Exelixis up as a promising young biotech company whose successes they will patiently cheer for from the sidelines. |
The Motley Fool
March 17, 2008
Brian Orelli |
Drugmakers That Make Rivals Green with Envy A look at some drugmakers with cash to spend: Pfizer...Wyeth... Novartis... Amylin Pharmaceuticals... Elan...Vertex Pharmaceuticals... Exelixis... |
The Motley Fool
May 10, 2005
Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice? |
The Motley Fool
February 15, 2011
Rich Smith |
What's Behind the Run-Up at Exelixis? One word: earnings. Shares of this tiny drug developer have taken off like a rocket. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
June 10, 2008
Brian Lawler |
Exelixis Secures Its Future In one of the more complicated financing deals ever made by a development-stage drugmaker, Exelixis brings in enough cash to keep guiding its lead drugs closer to market. |
The Motley Fool
September 28, 2006
Brian Lawler |
Exelixis' Growing Share Count The developing biopharmaceutical company announces a share offering. |
The Motley Fool
December 27, 2011
Brian Orelli |
Exelixis 2011: Not What the Doctor Ordered A tale of an inability to get a Special Protocol Assessment from the FDA. |
The Motley Fool
December 26, 2007
Brian Lawler |
Exelixis Awaits Bristol-Myers Decision Even if Bristol-Myers Squibb decides to discontinue their partnership, it might not mean the end of the road for Exelixis' cancer treatment. |
The Motley Fool
April 24, 2006
Stephen D. Simpson |
Novartis: A Good Story Repeated Whether sales were a little light or not, this is still a high-quality pharmaceutical company. The company not only has a good pipeline, but the valuation is still attractive without needing to make particularly aggressive assumptions. |
The Motley Fool
June 21, 2010
Luke Timmerman |
Bristol-Myers Dumps Exelixis Drug There is an exit payment for Exelixis. |
Bio-IT World
April 2006 |
News Blast PE Proteomics... Structural Genomics... Genome Express... Windber Win... |
